This recommendation follows the data safety monitoring board’s (DSMB) review of the blinded data from the first one-third of the 830 patients to be enrolled in two ongoing Phase III pivotal studies in Europe. The DSMB will conduct another review afte r two- thirds of the patients have been enrolled.
Hemospan is a hemoglobin-based oxygen transport agent designed to serve as oxygen therapeutic and as an alternative to blood transfusions. A key property of Hemospan is its high oxygen affinity which results in targeted oxygen delivery to tissues at risk of oxygen deprivation.